Pfizer CEO Albert Bourla Receives 21 Phantom Shares

What Happened

• Albert Bourla, Pfizer's Chairman & CEO, was granted 21 units representing phantom shares of Pfizer common stock on 2026-09-30. The units are reported at $28.52 each for a total reported value of $599. This was an award/acquisition (not an open-market purchase or sale).

Key Details

• Transaction date and price: 2026-09-30 at $28.52 per unit (total $599).
• Shares/units acquired: 21 phantom share units.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — each unit equals one phantom share of common stock. F2 — units were acquired under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and are settled in cash after the reporting person’s separation from service; they may be transferred into an alternative investment account at any time.
• Filing: Form 4 filed 2026-10-01 (appears timely).

Context

• These are derivative/phantom-share units (not actual common stock). They are settled in cash upon separation, so they do not immediately confer voting rights or actual equity ownership.
• Such deferred-compensation awards are routine for executives and should be viewed as compensation actions rather than direct buys/sells that signal market sentiment.